{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-033824","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.576720+00:00","generated_at":"2026-06-21T12:40:34.321086+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"INVO Bioscience receives Nasdaq delisting notice for low stockholders' equity","bullets":["Stockholders' equity of $1,287,224 as of Sept 30, 2022, below Nasdaq's $2.5M minimum requirement.","Must submit a compliance plan to Nasdaq by January 7, 2023 (45 days from November 23, 2022).","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Failure to regain compliance could result in delisting, with right to appeal to Nasdaq Hearings Panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-033824","json":"https://secwatch.observer/filing/0001493152-22-033824.json","markdown":"https://secwatch.observer/filing/0001493152-22-033824.md","text":"https://secwatch.observer/filing/0001493152-22-033824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222033824/0001493152-22-033824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222033824/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:40:34.321086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ba1172eb266245eacdb4442bdd994563824e654","claim":"INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"(the “Stockholders’ Equity Requirement). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,287,224, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Notice, the Company did not meet either of the alternative Nasdaq","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315222033824/0001493152-22-033824-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}